A Phase 1 interventional study of Oral single doses of MRX-4 and Oral multiple doses of MRX-4 in Safety, sponsored by MicuRx. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-09.
Sponsored by MicuRx · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A phase one study of the safety, tolerability, and pharmacokinetics of a new oxazolidinone antibiotic. Cohorts of healthy adults (female and male) will participate in:
single dose escalation study of increasing doses of MRX-4 given by mouth others will participate in multiple dose escalation cohorts of MRX-4 given twice daily by mouth.
other cohorts of subjects will participate in the study to evaluate the impact of concomitant food or Omeprazole on safety, tolerability and pharmacokinetics of MRX-4
MicuRx is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Single escalating oral doses of MRX-4 from 250 mg to 3000 mg
Drug: Oral single doses of MRX-4
Twice daily escalating oral doses of MRX-4 for 10 days: 500 mg, 750 mg, 1000 mg, and 1500 mg
Drug: Oral multiple doses of MRX-4
Impact of concomitant food or omeprazole on the pharmacokinetics of oral MRX-4.
Drug: MRX-4 co-administered with omeprazole
Single oral doses of placebo to match MRX-4
Drug: Oral single doses of placebo
Multiple oral doses of placebo given twice daily for 10 days to match MRX-4
Drug: Oral multiple doses of placebo
Oral placebo given on Day 1, Day 7 to match MRX-4 dosing with omeprazole
Drug: Placebo co-administered with omeprazole
Oral single escalating doses of MRX-4
Multiple ascending doses of MRX-4 given twice daily for 10 days
Drug page: OmeprazoleStudies of OmeprazoleOmeprazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
MRX-4 given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
Single doses of placebo to match MRX-4
Oral placebo given twice daily for 10 days to match the oral MRX-4
Placebo given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
Safety of single and multiple ascending doses of MRX-4
Summary of number of subjects with changes in vital signs, physical examinations, clinical lab data, ECG parameters and adverse events
Time frame: Screening through end of study visit on Day 7 (Part 1), Day 17 (Part II) and Day 14 (Part III)
Summary of concentration time data for MRX-4 and its metabolites
Concentration time data for MRX-4 and its metabolites in blood and urine
Time frame: Pre-dose through 72 hours post dose
Summary of the plasma concentration teim data for MRX-4 under fed or fasted conditions
Concentration time data for MRX-4 and its metabolites in blood and urine under fed and fasted conditions
Time frame: Pre-dose through 72 hours post dose
Safety of MRX-4 co-administered with omeprazole
Summary of the number of subjects with changes in vital signs, physical examinations, clinical lab data, ecg parameters and adverse events
Time frame: Screening through end of study on Day 14
Summary of the plasma concentration time data for MRX-4 co-administered with omeprazole
Concentation time data for MRX-4 and its metabolites in blood and urine with and without omeprazole
Time frame: Pre-dose through 72 hours post dose
No study locations are listed for this record.
Plan to share: No — The study results will be published in the future
No publications or documents are linked to this record.
Ran from Aug 2016 to primary completion in Feb 2017, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Omeprazole
MicuRx